Advertisement

International Urology and Nephrology

, Volume 4, Issue 4, pp 353–360 | Cite as

Treatment of Urogenital tuberculosis with Terivalidin

  • S. Kottász
  • A. Babics
Article

Abstract

Trivalidin, marketed by Milanese firm BRACCO, has been tested at the Department of Urology of the Budapest Medical University for 2 years and found to have a high tuberculostatic potency. Receiving daily doses of 750 mg, 50 patients showed essential improvement both subjectively and objectively and objectively. Laboratory analyses, cystoscopic pictures and roentgenograms made the subsidence of tuberculosis evident. Treatment with Terivalidin is promising also in cases of bilateral and solitary kidney tuberculosis. The drug enables the urologists to resort to conservative surgery in cases in which Terivalidin is promising also in cases of bilatgeral and solitary kidney tuberculosis. The drug enables the urologists to resort to conservative surgery in cases in which the patient responds only to Terivalidin so that, the urine having become negative, it is possible to eliminate the tuberculous focus (pole resection, cavernotomy).

A case is described where, owing to the tuberculostatic effect of the drug, some 45 per cent of the diseased left kidney could be saved by adquate heminephrectomy. In another case the disappearance of juxtavesical ureteral stricture and the resulting improvement of the right kidney made it possible to extirpoate he destroyed left kidney.

Neither of the two patients had complaints 12 months after the intervention; urinalysis, cystoscopy and all laboratory examinations gave normal values.

Keywords

Public Health Tuberculosis Laboratory Analysis Left Kidney Laboratory Examination 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Strata, A., Dell'Anna, A., Cacitti, G. B.: Kinetics and therapeutic activity of Terizidone in man.L'Ateneo Parmense 38, 43 (1967).Google Scholar
  2. 2.
    Wandruska, R.: Klinische Prüfung des Tuberkulostatikums Terizidone. Lecture held at the VIth symposium Tuberculosis Urogenitalis Europaeum, Budapest, 23–25 September, 1968.Google Scholar
  3. 3.
    Wandruska, R.: Klinische Prüfung des Tuberkulostatikums Terizidone.Riv. path. clin. tuberc. 12, 259 (1968).Google Scholar

Copyright information

© Akadémiai Kiadó 1972

Authors and Affiliations

  • S. Kottász
    • 1
  • A. Babics
    • 1
  1. 1.Department of UrologySemmelweis University Medical SchoolBudapest

Personalised recommendations